Healthcare
Live WireMerck’s Welireg‑Keytruda Combination Gains FDA Approval for Adjuvant Kidney Cancer
The clearance expands Merck’s oncology portfolio into the adjuvant setting, offering a new therapeutic option for patients at risk of disease recurrence and potentially increasing the market size for both drugs beyond their existing advanced‑disease indications.
15 JUN 20262 min readworld
The clearance expands Merck’s oncology portfolio into the adjuvant setting, offering a new therapeutic option for patients at risk of disease recurrence and potentially increasing the market size for both drugs beyond their existing advanced‑disease indications.
Sourced from KnowledgeLoop